nodes	percent_of_prediction	percent_of_DWPC	metapath
Telmisartan—ABCG2—Teniposide—lymphatic system cancer	0.16	0.203	CbGbCtD
Telmisartan—ABCG2—Mitoxantrone—lymphatic system cancer	0.112	0.142	CbGbCtD
Telmisartan—SLCO1B3—Methotrexate—lymphatic system cancer	0.101	0.128	CbGbCtD
Telmisartan—ABCC2—Vincristine—lymphatic system cancer	0.085	0.108	CbGbCtD
Telmisartan—ABCG2—Vincristine—lymphatic system cancer	0.0769	0.0975	CbGbCtD
Telmisartan—CYP2C19—Teniposide—lymphatic system cancer	0.0714	0.0906	CbGbCtD
Telmisartan—ABCC2—Methotrexate—lymphatic system cancer	0.0515	0.0653	CbGbCtD
Telmisartan—ABCG2—Methotrexate—lymphatic system cancer	0.0465	0.0591	CbGbCtD
Telmisartan—ABCB1—Mitoxantrone—lymphatic system cancer	0.0403	0.0511	CbGbCtD
Telmisartan—ABCB1—Vincristine—lymphatic system cancer	0.0277	0.0352	CbGbCtD
Telmisartan—ABCB1—Methotrexate—lymphatic system cancer	0.0168	0.0213	CbGbCtD
Telmisartan—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.0061	1	CbGdCrCtD
Telmisartan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00044	0.00214	CcSEcCtD
Telmisartan—Melaena—Methotrexate—lymphatic system cancer	0.00044	0.00214	CcSEcCtD
Telmisartan—Malaise—Bleomycin—lymphatic system cancer	0.000439	0.00214	CcSEcCtD
Telmisartan—Pruritus—Teniposide—lymphatic system cancer	0.000436	0.00212	CcSEcCtD
Telmisartan—Arrhythmia—Carmustine—lymphatic system cancer	0.000436	0.00212	CcSEcCtD
Telmisartan—Cystitis—Methotrexate—lymphatic system cancer	0.000435	0.00211	CcSEcCtD
Telmisartan—Cardiac disorder—Vincristine—lymphatic system cancer	0.000433	0.0021	CcSEcCtD
Telmisartan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000429	0.00208	CcSEcCtD
Telmisartan—Mental disorder—Carmustine—lymphatic system cancer	0.000428	0.00208	CcSEcCtD
Telmisartan—Vaginal infection—Methotrexate—lymphatic system cancer	0.000425	0.00207	CcSEcCtD
Telmisartan—Malnutrition—Carmustine—lymphatic system cancer	0.000425	0.00207	CcSEcCtD
Telmisartan—Erythema—Carmustine—lymphatic system cancer	0.000425	0.00207	CcSEcCtD
Telmisartan—Cough—Bleomycin—lymphatic system cancer	0.000425	0.00207	CcSEcCtD
Telmisartan—Angiopathy—Vincristine—lymphatic system cancer	0.000423	0.00206	CcSEcCtD
Telmisartan—Diarrhoea—Teniposide—lymphatic system cancer	0.000422	0.00205	CcSEcCtD
Telmisartan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00042	0.00204	CcSEcCtD
Telmisartan—Chest pain—Bleomycin—lymphatic system cancer	0.000415	0.00202	CcSEcCtD
Telmisartan—Myalgia—Bleomycin—lymphatic system cancer	0.000415	0.00202	CcSEcCtD
Telmisartan—Back pain—Carmustine—lymphatic system cancer	0.000411	0.002	CcSEcCtD
Telmisartan—Discomfort—Bleomycin—lymphatic system cancer	0.00041	0.00199	CcSEcCtD
Telmisartan—Mental disorder—Vincristine—lymphatic system cancer	0.000408	0.00199	CcSEcCtD
Telmisartan—Chills—Mitoxantrone—lymphatic system cancer	0.000407	0.00198	CcSEcCtD
Telmisartan—Bladder pain—Methotrexate—lymphatic system cancer	0.000407	0.00198	CcSEcCtD
Telmisartan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000406	0.00197	CcSEcCtD
Telmisartan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000399	0.00194	CcSEcCtD
Telmisartan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000398	0.00193	CcSEcCtD
Telmisartan—Oedema—Bleomycin—lymphatic system cancer	0.000398	0.00193	CcSEcCtD
Telmisartan—Erythema—Mitoxantrone—lymphatic system cancer	0.000395	0.00192	CcSEcCtD
Telmisartan—Infection—Bleomycin—lymphatic system cancer	0.000395	0.00192	CcSEcCtD
Telmisartan—Anaemia—Carmustine—lymphatic system cancer	0.000393	0.00191	CcSEcCtD
Telmisartan—Back pain—Vincristine—lymphatic system cancer	0.000393	0.00191	CcSEcCtD
Telmisartan—Vomiting—Teniposide—lymphatic system cancer	0.000392	0.00191	CcSEcCtD
Telmisartan—Sepsis—Methotrexate—lymphatic system cancer	0.000391	0.0019	CcSEcCtD
Telmisartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000389	0.00189	CcSEcCtD
Telmisartan—Asthenia—Fludarabine—lymphatic system cancer	0.000389	0.00189	CcSEcCtD
Telmisartan—Rash—Teniposide—lymphatic system cancer	0.000389	0.00189	CcSEcCtD
Telmisartan—Dermatitis—Teniposide—lymphatic system cancer	0.000389	0.00189	CcSEcCtD
Telmisartan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000387	0.00188	CcSEcCtD
Telmisartan—Headache—Teniposide—lymphatic system cancer	0.000386	0.00188	CcSEcCtD
Telmisartan—Pruritus—Fludarabine—lymphatic system cancer	0.000384	0.00186	CcSEcCtD
Telmisartan—Back pain—Mitoxantrone—lymphatic system cancer	0.000382	0.00186	CcSEcCtD
Telmisartan—Anorexia—Bleomycin—lymphatic system cancer	0.000379	0.00184	CcSEcCtD
Telmisartan—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000376	0.00183	CcSEcCtD
Telmisartan—Anaemia—Vincristine—lymphatic system cancer	0.000375	0.00182	CcSEcCtD
Telmisartan—Hypotension—Bleomycin—lymphatic system cancer	0.000371	0.00181	CcSEcCtD
Telmisartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000371	0.0018	CcSEcCtD
Telmisartan—Hypertension—Carmustine—lymphatic system cancer	0.000367	0.00178	CcSEcCtD
Telmisartan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000367	0.00178	CcSEcCtD
Telmisartan—Nausea—Teniposide—lymphatic system cancer	0.000366	0.00178	CcSEcCtD
Telmisartan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000365	0.00178	CcSEcCtD
Telmisartan—Vertigo—Vincristine—lymphatic system cancer	0.000365	0.00177	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000362	0.00176	CcSEcCtD
Telmisartan—Myalgia—Carmustine—lymphatic system cancer	0.000362	0.00176	CcSEcCtD
Telmisartan—Chest pain—Carmustine—lymphatic system cancer	0.000362	0.00176	CcSEcCtD
Telmisartan—Anxiety—Carmustine—lymphatic system cancer	0.000361	0.00175	CcSEcCtD
Telmisartan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000357	0.00174	CcSEcCtD
Telmisartan—Malaise—Mitoxantrone—lymphatic system cancer	0.000356	0.00173	CcSEcCtD
Telmisartan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000354	0.00172	CcSEcCtD
Telmisartan—Renal failure acute—Methotrexate—lymphatic system cancer	0.000354	0.00172	CcSEcCtD
Telmisartan—Hypertension—Vincristine—lymphatic system cancer	0.00035	0.0017	CcSEcCtD
Telmisartan—Oedema—Carmustine—lymphatic system cancer	0.000347	0.00169	CcSEcCtD
Telmisartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000346	0.00168	CcSEcCtD
Telmisartan—Myalgia—Vincristine—lymphatic system cancer	0.000346	0.00168	CcSEcCtD
Telmisartan—Visual disturbance—Methotrexate—lymphatic system cancer	0.000345	0.00168	CcSEcCtD
Telmisartan—Cough—Mitoxantrone—lymphatic system cancer	0.000345	0.00168	CcSEcCtD
Telmisartan—Infection—Carmustine—lymphatic system cancer	0.000345	0.00168	CcSEcCtD
Telmisartan—Vomiting—Fludarabine—lymphatic system cancer	0.000345	0.00168	CcSEcCtD
Telmisartan—Rash—Fludarabine—lymphatic system cancer	0.000342	0.00166	CcSEcCtD
Telmisartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000342	0.00166	CcSEcCtD
Telmisartan—Hypertension—Mitoxantrone—lymphatic system cancer	0.000341	0.00166	CcSEcCtD
Telmisartan—Pain—Bleomycin—lymphatic system cancer	0.00034	0.00165	CcSEcCtD
Telmisartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00034	0.00165	CcSEcCtD
Telmisartan—Headache—Fludarabine—lymphatic system cancer	0.00034	0.00165	CcSEcCtD
Telmisartan—Tachycardia—Carmustine—lymphatic system cancer	0.000339	0.00165	CcSEcCtD
Telmisartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000337	0.00164	CcSEcCtD
Telmisartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000337	0.00164	CcSEcCtD
Telmisartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000337	0.00164	CcSEcCtD
Telmisartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000335	0.00163	CcSEcCtD
Telmisartan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000332	0.00162	CcSEcCtD
Telmisartan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000331	0.00161	CcSEcCtD
Telmisartan—Oedema—Vincristine—lymphatic system cancer	0.000331	0.00161	CcSEcCtD
Telmisartan—Anorexia—Carmustine—lymphatic system cancer	0.000331	0.00161	CcSEcCtD
Telmisartan—Infection—Vincristine—lymphatic system cancer	0.000329	0.0016	CcSEcCtD
Telmisartan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000328	0.00159	CcSEcCtD
Telmisartan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000327	0.00159	CcSEcCtD
Telmisartan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000325	0.00158	CcSEcCtD
Telmisartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000324	0.00158	CcSEcCtD
Telmisartan—Hypotension—Carmustine—lymphatic system cancer	0.000324	0.00158	CcSEcCtD
Telmisartan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000323	0.00157	CcSEcCtD
Telmisartan—Oedema—Mitoxantrone—lymphatic system cancer	0.000323	0.00157	CcSEcCtD
Telmisartan—Nausea—Fludarabine—lymphatic system cancer	0.000322	0.00157	CcSEcCtD
Telmisartan—Infection—Mitoxantrone—lymphatic system cancer	0.00032	0.00156	CcSEcCtD
Telmisartan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00032	0.00156	CcSEcCtD
Telmisartan—Shock—Mitoxantrone—lymphatic system cancer	0.000317	0.00154	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000316	0.00154	CcSEcCtD
Telmisartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000316	0.00154	CcSEcCtD
Telmisartan—Urticaria—Bleomycin—lymphatic system cancer	0.000316	0.00154	CcSEcCtD
Telmisartan—Anorexia—Vincristine—lymphatic system cancer	0.000316	0.00154	CcSEcCtD
Telmisartan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000315	0.00153	CcSEcCtD
Telmisartan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000314	0.00153	CcSEcCtD
Telmisartan—Insomnia—Carmustine—lymphatic system cancer	0.000314	0.00153	CcSEcCtD
Telmisartan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000313	0.00152	CcSEcCtD
Telmisartan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000312	0.00152	CcSEcCtD
Telmisartan—Paraesthesia—Carmustine—lymphatic system cancer	0.000312	0.00151	CcSEcCtD
Telmisartan—Hypotension—Vincristine—lymphatic system cancer	0.00031	0.0015	CcSEcCtD
Telmisartan—Dyspnoea—Carmustine—lymphatic system cancer	0.000309	0.0015	CcSEcCtD
Telmisartan—Somnolence—Carmustine—lymphatic system cancer	0.000308	0.0015	CcSEcCtD
Telmisartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000308	0.00149	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000302	0.00147	CcSEcCtD
Telmisartan—Decreased appetite—Carmustine—lymphatic system cancer	0.000302	0.00147	CcSEcCtD
Telmisartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000301	0.00147	CcSEcCtD
Telmisartan—Insomnia—Vincristine—lymphatic system cancer	0.0003	0.00146	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0003	0.00146	CcSEcCtD
Telmisartan—Paraesthesia—Vincristine—lymphatic system cancer	0.000297	0.00145	CcSEcCtD
Telmisartan—Pain—Carmustine—lymphatic system cancer	0.000297	0.00144	CcSEcCtD
Telmisartan—Constipation—Carmustine—lymphatic system cancer	0.000297	0.00144	CcSEcCtD
Telmisartan—Breast disorder—Methotrexate—lymphatic system cancer	0.000296	0.00144	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000294	0.00143	CcSEcCtD
Telmisartan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000293	0.00142	CcSEcCtD
Telmisartan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00029	0.00141	CcSEcCtD
Telmisartan—Decreased appetite—Vincristine—lymphatic system cancer	0.000288	0.0014	CcSEcCtD
Telmisartan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000288	0.0014	CcSEcCtD
Telmisartan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000287	0.00139	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000286	0.00139	CcSEcCtD
Telmisartan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000286	0.00139	CcSEcCtD
Telmisartan—Fatigue—Vincristine—lymphatic system cancer	0.000286	0.00139	CcSEcCtD
Telmisartan—Asthenia—Bleomycin—lymphatic system cancer	0.000285	0.00139	CcSEcCtD
Telmisartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000284	0.00138	CcSEcCtD
Telmisartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000284	0.00138	CcSEcCtD
Telmisartan—Constipation—Vincristine—lymphatic system cancer	0.000283	0.00138	CcSEcCtD
Telmisartan—Pain—Vincristine—lymphatic system cancer	0.000283	0.00138	CcSEcCtD
Telmisartan—Asthma—Methotrexate—lymphatic system cancer	0.000283	0.00137	CcSEcCtD
Telmisartan—Pruritus—Bleomycin—lymphatic system cancer	0.000281	0.00137	CcSEcCtD
Telmisartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00028	0.00136	CcSEcCtD
Telmisartan—Eosinophilia—Methotrexate—lymphatic system cancer	0.00028	0.00136	CcSEcCtD
Telmisartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000278	0.00135	CcSEcCtD
Telmisartan—Pain—Mitoxantrone—lymphatic system cancer	0.000276	0.00134	CcSEcCtD
Telmisartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000276	0.00134	CcSEcCtD
Telmisartan—Body temperature increased—Carmustine—lymphatic system cancer	0.000274	0.00133	CcSEcCtD
Telmisartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000274	0.00133	CcSEcCtD
Telmisartan—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000271	0.00132	CcSEcCtD
Telmisartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000271	0.00132	CcSEcCtD
Telmisartan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000266	0.00129	CcSEcCtD
Telmisartan—Dysuria—Methotrexate—lymphatic system cancer	0.000264	0.00128	CcSEcCtD
Telmisartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000264	0.00128	CcSEcCtD
Telmisartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000263	0.00128	CcSEcCtD
Telmisartan—Abdominal pain—Vincristine—lymphatic system cancer	0.000262	0.00127	CcSEcCtD
Telmisartan—Body temperature increased—Vincristine—lymphatic system cancer	0.000262	0.00127	CcSEcCtD
Telmisartan—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00026	0.00127	CcSEcCtD
Telmisartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000256	0.00125	CcSEcCtD
Telmisartan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000256	0.00124	CcSEcCtD
Telmisartan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000255	0.00124	CcSEcCtD
Telmisartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000255	0.00124	CcSEcCtD
Telmisartan—Pneumonia—Methotrexate—lymphatic system cancer	0.000253	0.00123	CcSEcCtD
Telmisartan—Vomiting—Bleomycin—lymphatic system cancer	0.000253	0.00123	CcSEcCtD
Telmisartan—Infestation NOS—Methotrexate—lymphatic system cancer	0.000252	0.00123	CcSEcCtD
Telmisartan—Infestation—Methotrexate—lymphatic system cancer	0.000252	0.00123	CcSEcCtD
Telmisartan—Depression—Methotrexate—lymphatic system cancer	0.000251	0.00122	CcSEcCtD
Telmisartan—Rash—Bleomycin—lymphatic system cancer	0.000251	0.00122	CcSEcCtD
Telmisartan—Dermatitis—Bleomycin—lymphatic system cancer	0.00025	0.00122	CcSEcCtD
Telmisartan—Asthenia—Carmustine—lymphatic system cancer	0.000249	0.00121	CcSEcCtD
Telmisartan—Renal failure—Methotrexate—lymphatic system cancer	0.000248	0.0012	CcSEcCtD
Telmisartan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000245	0.00119	CcSEcCtD
Telmisartan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000244	0.00119	CcSEcCtD
Telmisartan—Haematuria—Methotrexate—lymphatic system cancer	0.00024	0.00117	CcSEcCtD
Telmisartan—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000238	0.00116	CcSEcCtD
Telmisartan—Epistaxis—Methotrexate—lymphatic system cancer	0.000238	0.00116	CcSEcCtD
Telmisartan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000238	0.00116	CcSEcCtD
Telmisartan—Asthenia—Vincristine—lymphatic system cancer	0.000238	0.00116	CcSEcCtD
Telmisartan—Diarrhoea—Carmustine—lymphatic system cancer	0.000237	0.00115	CcSEcCtD
Telmisartan—Nausea—Bleomycin—lymphatic system cancer	0.000236	0.00115	CcSEcCtD
Telmisartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000231	0.00113	CcSEcCtD
Telmisartan—Dizziness—Carmustine—lymphatic system cancer	0.000229	0.00112	CcSEcCtD
Telmisartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000227	0.0011	CcSEcCtD
Telmisartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.000225	0.00109	CcSEcCtD
Telmisartan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000223	0.00109	CcSEcCtD
Telmisartan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000222	0.00108	CcSEcCtD
Telmisartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000221	0.00107	CcSEcCtD
Telmisartan—Vomiting—Carmustine—lymphatic system cancer	0.000221	0.00107	CcSEcCtD
Telmisartan—Dizziness—Vincristine—lymphatic system cancer	0.000219	0.00106	CcSEcCtD
Telmisartan—Rash—Carmustine—lymphatic system cancer	0.000219	0.00106	CcSEcCtD
Telmisartan—Dermatitis—Carmustine—lymphatic system cancer	0.000219	0.00106	CcSEcCtD
Telmisartan—Visual impairment—Methotrexate—lymphatic system cancer	0.000218	0.00106	CcSEcCtD
Telmisartan—Headache—Carmustine—lymphatic system cancer	0.000217	0.00106	CcSEcCtD
Telmisartan—Eye disorder—Methotrexate—lymphatic system cancer	0.000211	0.00103	CcSEcCtD
Telmisartan—Tinnitus—Methotrexate—lymphatic system cancer	0.000211	0.00103	CcSEcCtD
Telmisartan—Vomiting—Vincristine—lymphatic system cancer	0.000211	0.00102	CcSEcCtD
Telmisartan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00021	0.00102	CcSEcCtD
Telmisartan—Rash—Vincristine—lymphatic system cancer	0.000209	0.00102	CcSEcCtD
Telmisartan—Dermatitis—Vincristine—lymphatic system cancer	0.000209	0.00101	CcSEcCtD
Telmisartan—Headache—Vincristine—lymphatic system cancer	0.000208	0.00101	CcSEcCtD
Telmisartan—Nausea—Carmustine—lymphatic system cancer	0.000206	0.001	CcSEcCtD
Telmisartan—Angiopathy—Methotrexate—lymphatic system cancer	0.000205	0.000998	CcSEcCtD
Telmisartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000205	0.000997	CcSEcCtD
Telmisartan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000204	0.000993	CcSEcCtD
Telmisartan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000204	0.000991	CcSEcCtD
Telmisartan—Rash—Mitoxantrone—lymphatic system cancer	0.000203	0.000989	CcSEcCtD
Telmisartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000203	0.000988	CcSEcCtD
Telmisartan—Chills—Methotrexate—lymphatic system cancer	0.000203	0.000987	CcSEcCtD
Telmisartan—Headache—Mitoxantrone—lymphatic system cancer	0.000202	0.000982	CcSEcCtD
Telmisartan—Mental disorder—Methotrexate—lymphatic system cancer	0.000198	0.000964	CcSEcCtD
Telmisartan—Malnutrition—Methotrexate—lymphatic system cancer	0.000197	0.000957	CcSEcCtD
Telmisartan—Erythema—Methotrexate—lymphatic system cancer	0.000197	0.000957	CcSEcCtD
Telmisartan—Nausea—Vincristine—lymphatic system cancer	0.000197	0.000957	CcSEcCtD
Telmisartan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000193	0.000938	CcSEcCtD
Telmisartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000192	0.000932	CcSEcCtD
Telmisartan—Back pain—Methotrexate—lymphatic system cancer	0.000191	0.000926	CcSEcCtD
Telmisartan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000183	0.000888	CcSEcCtD
Telmisartan—Anaemia—Methotrexate—lymphatic system cancer	0.000182	0.000885	CcSEcCtD
Telmisartan—Malaise—Methotrexate—lymphatic system cancer	0.000178	0.000863	CcSEcCtD
Telmisartan—Vertigo—Methotrexate—lymphatic system cancer	0.000177	0.00086	CcSEcCtD
Telmisartan—Cough—Methotrexate—lymphatic system cancer	0.000172	0.000835	CcSEcCtD
Telmisartan—Arthralgia—Methotrexate—lymphatic system cancer	0.000168	0.000815	CcSEcCtD
Telmisartan—Chest pain—Methotrexate—lymphatic system cancer	0.000168	0.000815	CcSEcCtD
Telmisartan—Myalgia—Methotrexate—lymphatic system cancer	0.000168	0.000815	CcSEcCtD
Telmisartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000167	0.000809	CcSEcCtD
Telmisartan—Discomfort—Methotrexate—lymphatic system cancer	0.000166	0.000805	CcSEcCtD
Telmisartan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000161	0.000781	CcSEcCtD
Telmisartan—Infection—Methotrexate—lymphatic system cancer	0.00016	0.000776	CcSEcCtD
Telmisartan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000158	0.000766	CcSEcCtD
Telmisartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000157	0.000765	CcSEcCtD
Telmisartan—Skin disorder—Methotrexate—lymphatic system cancer	0.000156	0.000759	CcSEcCtD
Telmisartan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000155	0.000755	CcSEcCtD
Telmisartan—Anorexia—Methotrexate—lymphatic system cancer	0.000153	0.000745	CcSEcCtD
Telmisartan—Hypotension—Methotrexate—lymphatic system cancer	0.00015	0.00073	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000146	0.000712	CcSEcCtD
Telmisartan—Insomnia—Methotrexate—lymphatic system cancer	0.000145	0.000707	CcSEcCtD
Telmisartan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000144	0.000702	CcSEcCtD
Telmisartan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000143	0.000697	CcSEcCtD
Telmisartan—Somnolence—Methotrexate—lymphatic system cancer	0.000143	0.000695	CcSEcCtD
Telmisartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000141	0.000688	CcSEcCtD
Telmisartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.00014	0.000679	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000139	0.000675	CcSEcCtD
Telmisartan—Fatigue—Methotrexate—lymphatic system cancer	0.000139	0.000674	CcSEcCtD
Telmisartan—Pain—Methotrexate—lymphatic system cancer	0.000137	0.000668	CcSEcCtD
Telmisartan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000132	0.000644	CcSEcCtD
Telmisartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000131	0.000639	CcSEcCtD
Telmisartan—Urticaria—Methotrexate—lymphatic system cancer	0.000128	0.000621	CcSEcCtD
Telmisartan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000127	0.000618	CcSEcCtD
Telmisartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000127	0.000618	CcSEcCtD
Telmisartan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000118	0.000576	CcSEcCtD
Telmisartan—Asthenia—Methotrexate—lymphatic system cancer	0.000115	0.000561	CcSEcCtD
Telmisartan—Pruritus—Methotrexate—lymphatic system cancer	0.000114	0.000553	CcSEcCtD
Telmisartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.00011	0.000535	CcSEcCtD
Telmisartan—Dizziness—Methotrexate—lymphatic system cancer	0.000106	0.000517	CcSEcCtD
Telmisartan—Vomiting—Methotrexate—lymphatic system cancer	0.000102	0.000497	CcSEcCtD
Telmisartan—Rash—Methotrexate—lymphatic system cancer	0.000101	0.000493	CcSEcCtD
Telmisartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000101	0.000492	CcSEcCtD
Telmisartan—Headache—Methotrexate—lymphatic system cancer	0.000101	0.00049	CcSEcCtD
Telmisartan—Nausea—Methotrexate—lymphatic system cancer	9.55e-05	0.000464	CcSEcCtD
